Podolecki Tomasz S, Lenarczyk Radoslaw K, Kowalczyk Jacek P, Jedrzejczyk-Patej Ewa K, Chodor Piotr K, Mazurek Michal H, Francuz Pawel J, Streb Witold A, Mitrega Katarzyna A, Kalarus Zbigniew F
Department of Cardiology, Congenital Heart Diseases and Electrotherapy, Silesian Center for Heart Diseases.
Department of Cardiology, School of Medicine, Division of Dentistry, Zabrze, Poland.
Coron Artery Dis. 2018 Dec;29(8):681-686. doi: 10.1097/MCA.0000000000000662.
The primary aim of the study was to evaluate risk factors for ventricular fibrillation/sustained ventricular tachycardia (VF/VT) and to develop the risk score for prediction of VF/VT in patients with ST-segment elevation myocardial infarction (STEMI) treated invasively. The secondary aim was to assess the effect of VF/VT on mortality depending on timing of arrhythmia.
We analyzed 4363 consecutive patients with STEMI treated invasively. Among them, 163 patients with pre-reperfusion arrhythmia were excluded from the study. Group ventricular arrhythmias (VA) encompassed patients with VF/VT - those with reperfusion-induced arrhythmia were included into group VA1, whereas group VA2 consisted of patients with postreperfusion arrhythmia. The control group comprised patients free of VF/VT.
VF or VT occurred in 313 (7.45%) patients - group VA1 encompassed 103 (32.9%) and group AV2 210 (67.1%) patients. Cardiogenic shock on admission [hazard ratio (HR) 3.5], new-onset atrial fibrillation (HR 2.1), incomplete revascularization (HR 1.7), prior myocardial infarction (HR 1.6) and symptom-to-balloon time more than 3 h (HR 1.3) were the independent predictors of VF/VT occurrence. In group VA2, the in-hospital and long-term mortality were 4- and 1.5-fold higher than in the arrhythmia-free population (20.5 vs. 4.5% and 36.2 vs. 22.6%, respectively; P<0.001). On the contrary, in group VA1, the long-term mortality was not significantly higher compared with the control group (26.2 vs. 22.6%; P=NS), whereas in-hospital mortality was almost three-fold increased (12.5 vs. 4.5%, respectively; P<0.001).
The risk score based on simple clinical parameters might be useful for risk stratification for VF/VT in patients with STEMI. The predictive value of VF/VT was strongly dependent on timing of arrhythmia.
本研究的主要目的是评估室颤/持续性室性心动过速(VF/VT)的危险因素,并制定风险评分以预测接受侵入性治疗的ST段抬高型心肌梗死(STEMI)患者发生VF/VT的风险。次要目的是根据心律失常发生的时间评估VF/VT对死亡率的影响。
我们分析了4363例连续接受侵入性治疗的STEMI患者。其中,163例有再灌注前心律失常的患者被排除在研究之外。室性心律失常(VA)组包括发生VF/VT的患者——再灌注诱导的心律失常患者被纳入VA1组,而VA2组由再灌注后心律失常患者组成。对照组包括无VF/VT的患者。
313例(7.45%)患者发生VF或VT——VA1组包括103例(32.9%)患者,VA2组包括210例(67.1%)患者。入院时发生心源性休克(风险比[HR] 3.5)、新发房颤(HR 2.1)、血管再通不完全(HR 1.7)、既往心肌梗死(HR 1.6)以及症状出现至球囊扩张时间超过3小时(HR 1.3)是VF/VT发生的独立预测因素。在VA2组中,住院和长期死亡率分别比无心律失常人群高4倍和1.5倍(分别为20.5%对4.5%和36.2%对22.6%;P<0.001)。相反,在VA1组中,长期死亡率与对照组相比无显著升高(26.2%对22.6%;P=无显著性差异),而住院死亡率几乎增加了三倍(分别为12.5%对4.5%;P<0.001)。
基于简单临床参数的风险评分可能有助于对STEMI患者的VF/VT进行风险分层。VF/VT的预测价值强烈依赖于心律失常发生的时间。